Strategic partnerships Systems Oncology has secured a global license with Bayer for ERSO, signaling openness to collaboration with big pharma and potential co-development or licensing deals that could be expanded to additional targets or indications.

Early stage opportunities With preclinical programs and rapid platform-driven asset generation, there are opportunities to engage in sponsored research, strategic partnerships, or milestone-based collaborations to leverage their multimodal RNA technology in oncology and other polygenic diseases.

AI driven discovery Their AI-based approach and recognition in AI for Drug Discovery positioning can be leveraged to pitch joint R&D initiatives, data-sharing collaborations, or technology licensing that accelerates target discovery and preclinical validation.

Funding and scale path Given the small team size and $1M-$10M revenue, there is a clear path for high-value collaborations, in-licensing of assets, or multi-year development deals with milestones tailored to a lean operation and scalable commercialization.

Market readiness Recent award recognition and established industry relationships suggest credibility with investors and partners; approach should emphasize expedited translational programs, regulatory strategy support, and access to a pipeline that can diversify therapeutic modalities in oncology and beyond.